Abstract
To compare long-term virologic benefits of antiretroviral regimens in persons with advanced human immunodeficiency virus (HIV) disease, a randomized, open-label study was conducted of 517 subjects with no or limited previous experience with antiretroviral therapy. Subjects received lamivudine plus zidovudine and indinavir (indinavir group), efavirenz plus indinavir (efavirenz + indinavir group), or nelfinavir plus indinavir (nelfinavir + indinavir group) and were monitored for 2.1 years. Virologic failure was lower in the efavirenz + indinavir group (P = .04) and higher in the nelfinavir + indinavir group (P = .006), compared with that in the indinavir group. No difference in grade 3 or 4 adverse event rates in the efavirenz + indinavir group (P = .97) and a trend toward an increased rate in the nelfinavir + indinavir group (P = .07), compared with the indinavir group, were noted. A 4-drug regimen containing efavirenz plus indinavir resulted in a superior virologic response, whereas one containing nelfinavir plus indinavir resulted in an inferior response and a greater likelihood of toxicity.
Original language | English (US) |
---|---|
Pages (from-to) | 625-634 |
Number of pages | 10 |
Journal | Journal of Infectious Diseases |
Volume | 188 |
Issue number | 5 |
DOIs | |
State | Published - Sep 1 2003 |
ASJC Scopus subject areas
- Immunology and Allergy
- Infectious Diseases